An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

NJ Ashton, A Hye, AP Rajkumar, A Leuzy… - Nature Reviews …, 2020 - nature.com
Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology
at the earliest stage of some neurodegenerative disorders, but do not have the scalability …

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the …

P Lewczuk, P Riederer, SE O'bryant… - The world journal of …, 2018 - Taylor & Francis
In the 12 years since the publication of the first Consensus Paper of the WFSBP on
biomarkers of neurodegenerative dementias, enormous advancement has taken place in …

Human CNS barrier-forming organoids with cerebrospinal fluid production

L Pellegrini, C Bonfio, J Chadwick, F Begum, M Skehel… - Science, 2020 - science.org
INTRODUCTION The choroid plexus is a secretory epithelial tissue of the central nervous
system (CNS) responsible for cerebrospinal fluid (CSF) production and functions as a barrier …

Molecular biomarkers of Alzheimer's disease: progress and prospects

T Lashley, JM Schott, P Weston… - Disease models & …, 2018 - journals.biologists.com
The neurodegenerative disorder Alzheimer's disease is characterised by the formation of β-
amyloid plaques and neurofibrillary tangles in the brain parenchyma, which cause synapse …

Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

SE O'Bryant, MM Mielke, RA Rissman, S Lista… - Alzheimer's & …, 2017 - Elsevier
The last decade has seen a substantial increase in research focused on the identification of
blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based …

Serum IL-6, sAXL, and YKL-40 as systemic correlates of reduced brain structure and function in Alzheimer's disease: results from the DELCODE study

F Brosseron, A Maass, L Kleineidam… - Alzheimer's research & …, 2023 - Springer
Background Neuroinflammation constitutes a pathological hallmark of Alzheimer's disease
(AD). Still, it remains unresolved if peripheral inflammatory markers can be utilized for …

Development of proteomic prediction models for transition to psychotic disorder in the clinical high-risk state and psychotic experiences in adolescence

D Mongan, M Föcking, C Healy, SR Susai… - JAMA …, 2021 - jamanetwork.com
Importance Biomarkers that are predictive of outcomes in individuals at risk of psychosis
would facilitate individualized prognosis and stratification strategies. Objective To …

A decade of blood biomarkers for Alzheimer's disease research: an evolving field, improving study designs, and the challenge of replication

L Shi, AL Baird, S Westwood, A Hye… - Journal of …, 2018 - content.iospress.com
Blood-based biomarkers represent a less invasive and potentially cheaper approach for
aiding Alzheimer's disease (AD) detection compared with cerebrospinal fluid and some …

[HTML][HTML] Recent evidence in epigenomics and proteomics biomarkers for early and minimally invasive diagnosis of Alzheimer's and Parkinson's diseases

S Mayo, J Benito-León, C Peña-Bautista… - Current …, 2021 - ncbi.nlm.nih.gov
Background: Alzheimer's (AD) and Parkinson's diseases (PD) show deposits of improperly
folded modified proteins. Protein expression mechanisms are involved since the early …

Integrating amyloid and tau imaging with proteomics and genomics in Alzheimer's disease

G Vilkaite, J Vogel, N Mattsson-Carlgren - Cell Reports Medicine, 2024 - cell.com
Alzheimer's disease (AD) is the most common neurodegenerative disease and is
characterized by the aggregation of β-amyloid (Aβ) and tau in the brain. Breakthroughs in …